Form 4: Liquidia CMO Sells Shares for Tax Obligations

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, reported the sale of 21,142 common shares at $37.43 to cover tax liabilities from vested equity awards, as part of a pre-arranged 10b5-1 plan.

Summary

• Chief Medical Officer Rajeev Saggar reported transactions involving Liquidia Corp common stock.
• Acquired 3,531 common shares and 17,945 common shares from vested Performance Stock Units (PSUs) on January 9, 2026.
• Sold 21,142 common shares at a price of $37.43 per share on January 12, 2026.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• The shares were sold to cover tax obligations associated with the settlement of Restricted Stock Units (RSUs) initially granted on January 11, 2023, January 11, 2024, and January 11, 2025.
• Following these reported transactions, Rajeev Saggar beneficially owns 176,883 direct common shares.
• Beneficial ownership also includes 20,833 unvested RSUs from the January 11, 2023 grant, 28,246 unvested RSUs from the January 11, 2024 grant, 53,835 unvested RSUs from the January 11, 2025 grant, and 2,221 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax purposes, pre-planned under a Rule 10b5-1 plan. This type of transaction is neutral in terms of operational impact or management's confidence in the company's future.

Positives

• Vesting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) indicates the achievement of performance or time-based milestones for the executive.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, demonstrating planned and compliant insider trading practices.

Negatives

• The sale of common stock by a Chief Medical Officer, even if for tax purposes, reduces their direct equity stake in the company.

Risks

• Potential for negative market perception if the sale is misinterpreted as a lack of confidence, despite being for tax purposes and under a 10b5-1 plan.

Future Outlook

N/A

Management Comments

• The shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and tax obligations, which is a common occurrence across all industries for executives receiving stock-based awards. It does not provide specific insights into broader industry trends or the competitive landscape.

Stakeholder Impact

• Shareholders: Minor dilution from vested shares, but the sale is for tax purposes and pre-planned, suggesting minimal impact on investor confidence.
• Employees: Reflects standard equity compensation practices for executives within the company.

Next Steps

• Continued vesting of remaining unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) according to their respective schedules.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider sale by the Chief Medical Officer to cover tax liabilities associated with vested equity awards. Such transactions are common and do not typically reflect a change in management's outlook or the company's fundamentals. Therefore, it provides no new information to warrant a change in investment recommendation; a 'hold' stance is maintained based on existing company analysis.

Keywords

Liquidia Corp, LQDA, Form 4, insider trading, stock sale, equity compensation, Rule 10b5-1, Chief Medical Officer, Rajeev Saggar, common stock, PSUs, RSUs, tax obligations